Drug Profile
Avacincaptad pegol - IVERIC bio
Alternative Names: Anti-C5 aptamer; ARC-1905; Avacincaptad pegol sodium; IZERVAY; ZimuraLatest Information Update: 24 Mar 2024
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Developer IVERIC bio
- Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dry age-related macular degeneration
- Phase III Stargardt disease
- Phase II Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
Most Recent Events
- 24 Mar 2024 Phase-III clinical trials in Stargardt disease (unspecified route), prior to March 2024 (Iveric Bio pipeline, March 2024)
- 04 Nov 2023 Efficacy and adverse events data from the phase III GATHER2 trial in geographic atrophy (GA) secondary to Dry age-related macular degeneration released by IVERIC bio
- 18 Sep 2023 Efficacy and adverse events data from phase-III GATHER2 trial in Dry age-related macular degeneration released by Iveric Bio